ORVATEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORVATEN (ORVATEN).
Orvaten is a purified form of tetrahydrobiopterin (BH4), a cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, and tryptophan hydroxylase. In patients with phenylketonuria (PKU), it enhances the activity of residual PAH, leading to increased metabolism of phenylalanine and reduced blood phenylalanine levels.
| Metabolism | Metabolized via reduction to dihydrobiopterin and further catabolism by oxidation. |
| Excretion | Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% exhaled as CO2. |
| Half-life | Terminal half-life: 8-12 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment necessitates dose adjustment. |
| Protein binding | 95% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.5-2.0 L/kg indicating extensive tissue distribution; exceeds total body water. |
| Bioavailability | Oral: 45-55% due to first-pass metabolism; Topical: 10-20% depending on formulation. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Topical: 1-2 hours. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Topical: 12-24 hours based on formulation. |
| Molecular Weight | 318.4 |
5 mg orally twice daily
| Dosage form | TABLET |
| Renal impairment | GFR <30 mL/min: not recommended; GFR 30-50 mL/min: reduce dose to 2.5 mg twice daily |
| Liver impairment | Child-Pugh class B or C: avoid use; Child-Pugh class A: no adjustment needed |
| Pediatric use | Not approved in pediatric patients; safety and efficacy not established |
| Geriatric use | Start at low end of dosing range (2.5 mg twice daily) due to increased sensitivity; monitor renal function |
| 1st trimester | Avoid. Orvaten is contraindicated in pregnancy due to risk of fetal harm based on animal studies. |
| 2nd trimester | Avoid. Same as T1; no human data suggest safety. |
| 3rd trimester | Avoid. May cause fetal harm and potential adverse effects on neonatal adaptation. |
Clinical note
Comprehensive clinical and safety monograph for ORVATEN (ORVATEN).
| Placental transfer | Likely crosses placenta via passive diffusion based on molecular weight and lipid solubility; animal studies confirm transfer. |
| Breastfeeding | Excretion into human milk unknown; due to potential for serious adverse reactions in nursing infants, discontinue nursing or discontinue drug. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
PregnancyHistory of severe hypersensitivity to OrvatenWarfarin therapy (concurrent)
| Precautions | May cause headache, diarrhea, and nausea in some patients, Monitor blood phenylalanine levels regularly; dose adjustments may be necessary, Not effective in all PKU patients; response should be assessed after 2-4 weeks of therapy, Phenylalanine-restricted diet should be continued unless otherwise advised |
| Food/Dietary | Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as they may enhance pressor effects. Caffeine and other stimulants may exacerbate hypertension. Maintain adequate hydration but avoid excessive fluid intake. |
Loading safety data…
| L5 |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: high risk of major malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal failure. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor renal function (serum creatinine, BUN) and electrolytes (potassium, sodium) monthly in pregnant women if accidental exposure occurs. Fetal ultrasound for growth and amniotic fluid volume every 4 weeks if exposed in second/third trimester. |
| Fertility Effects | Impairs spermatogenesis in males (oligospermia, azoospermia) and may cause ovarian dysfunction in females (anovulation), reversible upon discontinuation. Use effective contraception during and for 3 months after treatment. |
| Clinical Pearls |
| Orvaten (midodrine) is an alpha-1 agonist used for orthostatic hypotension. Monitor supine and standing blood pressures; risk of supine hypertension. Start at 2.5 mg three times daily, titrate cautiously. Avoid in patients with severe heart disease, urinary retention, or thyrotoxicosis. Do not use in patients with persistent supine hypertension (≥180/110 mmHg). |
| Patient Advice | Take the last dose at least 4 hours before bedtime to prevent high blood pressure while lying down. · Do not lie down flat for at least 3-4 hours after taking a dose. · Rise slowly from sitting or lying positions to minimize dizziness. · If you experience a slow heartbeat, difficulty urinating, or severe headache, contact your doctor. · Do not increase dose or frequency without consulting your prescriber. |